Using its proprietary bioprocessing technology, Cellesce is scaling the production of breast organoids for drug discovery research – with plans to expand into other areas of unmet medical need, says CEO.
Small molecule manufacturing can result in product loss, as the materials manufactured come into contact with internal surfaces thereby impacting drying and creating disruptions in efficency and cost-effectivness.
The Anglo-Swedish company will cut the positions from the site by 2020, with a consultation on the process initiated yesterday, a workers union claimed.
C2 Pharma acquires digoxin API product portfolio from Noblius to secure supply of the ingredient, after disruption of the supply of the API for a number of years.
Thermo Fisher Scientific bolsters its gene therapy capabilities by acquiring Brammer Bio for $1.7bn, as the market becomes an ‘increasing focus’ for customers.
The four-hospital health system, Health Quest, will use IBM Watson for Clinical Trial Matching to match patients to clinical trials throughout its hospital.
AlzProtect is collaborating with Parexel Biotech to advance a Phase IIa clinical trial of its lead candidate, AZP2006, which is being developed for the treatment of a rare neurodegenerative disease.
The clinical data analytics platform firm has raised $75m since 2015 and will continue to enhance both the platform and applications with new capabilities, says CEO.
Clinical AI, no matter how sophisticated, cannot work on its own, says Life Image CEO, who predicts that CROs will either adapt or be disrupted by smaller companies with digital access capabilities.
WuXi STA becomes the preferred CDMO partner for Beta Pharma as the company launches a Phase II clinical trial in China and begins preclinical research for an additional target.
Cure Pharma expands its DEA license to include authorization to manufacture both cannabis plant extracts and CBD within the scope of its patent portfolio.
BlueCloud by HealthCarePoint releases DDIT mechanisms to create an Uber-like service for the health care industry – connecting providers and consumers, such a sponsors and CROs.
Cambrex completes expansion of its R&D laboratory at its Milan site and adds a 12,000-liter reactor to its manufacturing facility during a $3m investment.
Synteract is opening a new office in Swansea, Wales in response to increased demand across its core therapeutic areas for both full-service work and more consultative, standalone projects, says CEO.
WCG’s new SiteReady solution looks to alleviate the challenges facing research teams, helping clinical trial sites remain “highly ranked” with sponsors.
As clinical trials create large amounts of data, and researchers seize the opportunity to use de-identified data as a means to develop and discovery, managing the information has become more and more complex.
There is a common and often unchallenged perception that manufacturing quality standards in pharmerging countries are worrisome, but Lee Newton of Lonza argues this is not the reality.
Optibrium develops software for drug discovery and today announces a collaboration with InfoChem GmbH, a cheminformatics company, to provide users with a computer-aided synthesis design tool.
Evotec is partnering with a global non-profit research group to develop a pipeline of novel antibiotics after integrating Sanofi’s infectious disease unit last year.
The global software consulting company N-Side recently launched an end-to-end clinical trial supply chain management solution to enable “agile” decision making and reduce drug waste.
Lonza and Israel-based Sheba Medical collaborate to use the CDMO’s manufacturing platform for point-of-care genetically engineered human CAR-T cell production.
Alternatives to the transactional RFP-bid defense structure “invite greater creativity and innovative options” into sourcing discussions, says Syneos executive.
In response to a growing interest in alternative testing methods, SenzaGen signs a license agreement with MB Research Labs to expand the use of its animal-free testing platform.
ACG announces plans to grow its Latin American presence with its newest capsule production plant in Brazil, as it continues to expand its facilities in Asia-Pacific and Europe.
Non-profit organisation, Civica, sees membership reach over 800 hospitals as part of its plan to secure the supply of generic medicine in short supply.
The FDA is addressing increasingly complex eligibility criteria in an effort to expand patient participation in cancer clinical trials, a move which will help shorten study recruitment timelines, among several other benefits to both researchers and patients,...
The clinical informatics company Ovation.io secures $5m in Series A funding to expand its platform designed to help diagnostic labs become a “keystone of precision medicine in their community,” says CEO.
Noramco partners with Nemus to produce an analogue of cannabidiol that possesses greater bioavailability, that could be used to treat diseases of the retina.
Bridging the gap between clinical care and research means creating two-way collaboration, improving the way in which data is collected, organized, shared – and engaging EHR vendors, says conference panelist.
US FDA announces that a new generic for valsartan will reach the market, after prioritising the review of the product to alleviate shortages resulting from recalled products.
